Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Haemonetics Corporation Common Stock (NY:HAE)

71.47 +1.37 (+1.95%)
Streaming Delayed Price Updated: 11:43 AM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
3 Value Stocks with Open Questions
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
News headline image
1 Cash-Producing Stock Worth Your Attention and 2 Facing Challenges
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
1 Small-Cap Stock Worth Your Attention and 2 We Avoid
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
3 Low-Volatility Stocks We Think Twice About
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Why Haemonetics (HAE) Shares Are Trading Lower Today
Shares of blood products company Haemonetics (NYSE:HAE). fell 4.3% in the afternoon session after Needham downgraded the stock from 'Buy' to 'Hold', citing concerns about growing competition. 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Haemonetics (HAE) Stock Is Down Today
Shares of blood products company Haemonetics (NYSE:HAE). fell 2.1% in the morning session after Citigroup downgraded the stock to "Neutral" from "Buy." 
Via StockStory
Topics Economy
News headline image
Teleflex, Solventum, Haemonetics, Centene, and Molina Healthcare Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy
News headline image
3 Reasons to Sell HAE and 1 Stock to Buy Instead
Although Haemonetics (currently trading at $74.04 per share) has gained 6.7% over the last six months, it has trailed the S&P 500’s 13% return during that period. This may have investors wondering how... 
Via StockStory
Topics Stocks Supply Chain
News headline image
1 Mooning Stock with Impressive Fundamentals and 2 We Ignore
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage... 
Via StockStory
Topics Artificial Intelligence
News headline image
5 Insightful Analyst Questions From Haemonetics’s Q3 Earnings Call
Haemonetics’ third quarter results were met with a significant positive market reaction, reflecting both a beat on Wall Street’s revenue and profit expectations and effective execution across its core... 
Via StockStory
Topics Earnings
News headline image
SG Capital Dumps Nearly 732,000 Haemonetics Shares Worth $59.1 Million ↗
SG Capital Dumps Nearly 732,000 Haemonetics Shares Worth $59.1 Million 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Haemonetics Stock Was on Fire Thursday ↗
The hematology specialist delivered a satisfying beat-and-raise fiscal second quarter. 
Via The Motley Fool
News headline image
HAE Q3 Deep Dive: Margin Expansion and Portfolio Rationalization Drive Outperformance
Blood products company Haemonetics (NYSE:HAE). announced better-than-expected revenue in Q3 CY2025, but sales fell by 5.3% year on year to $327.3 million. Its non-GAAP profit of $1.27 per share was... 
Via StockStory
News headline image
Why Are Haemonetics (HAE) Shares Soaring Today
Shares of blood products company Haemonetics (NYSE:HAE). jumped 22.1% in the morning session after the company reported third-quarter results that surpassed analyst expectations and raised its... 
Via StockStory
Topics Artificial Intelligence Economy Government
News headline image
Datadog, Fastly, Planet Fitness, Air Products And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Haemonetics (NYSE:HAE) Delivers Impressive Q3, Stock Jumps 12.8%
Blood products company Haemonetics (NYSE:HAE). reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell by 5.3% year on year to $327.3 million. Its non-GAAP profit of $1.27 per... 
Via StockStory
News headline image
What To Expect From Haemonetics’s (HAE) Q3 Earnings
Blood products company Haemonetics (NYSE:HAE). will be announcing earnings results this Thursday morning. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Russell 2000 Stocks We Think Twice About
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
News headline image
Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings?
Over the last six months, Haemonetics’s shares have sunk to $51.21, producing a disappointing 18.2% loss - a stark contrast to the S&P 500’s 24.4% gain. This might have investors contemplating their... 
Via StockStory
Topics Stocks Supply Chain
News headline image
3 Healthcare Stocks We Find Risky
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
News headline image
Unpacking Q2 Earnings: Haemonetics (NYSE:HAE) In The Context Of Other Medical Devices & Supplies - Specialty Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at medical devices & supplies - specialty... 
Via StockStory
News headline image
Medical Devices & Supplies - Specialty Stocks Q2 Results: Benchmarking Haemonetics (NYSE:HAE)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at medical devices & supplies - specialty... 
Via StockStory
News headline image
1 Stock Under $50 to Own for Decades and 2 Facing Headwinds
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
News headline image
How Do Investors Really Feel About Haemonetics Corp? ↗
 
Via Benzinga
News headline image
Dentsply Sirona, Acadia Healthcare, and Haemonetics Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
News headline image
1 Small-Cap Stock with Competitive Advantages and 2 We Turn Down
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks Walking a Fine Line
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
Bausch + Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential... 
Via StockStory
Topics Economy Government World Trade
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.